Huntington's Disease Epidemiology Forecast 2025-2034

Huntington's disease is a rare inherited brain disorder that leads to progressive cognitive, psychiatric, and movement symptoms. Early signs include small involuntary movements and poor coordination, among others. The prevalence of Huntington's disease is estimated to be 3 to 7 per 100,000 people of European ancestry. The disorder appears to occur less commonly in people of Japanese, African, and Chinese descent.

Huntington’s Disease (HD) Epidemiology Forecast Report Coverage

The “Huntington’s Disease (HD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Huntington’s disease (HD). It projects the future incidence and prevalence rates of Huntington’s disease (HD) across various populations. The study covers age, gender, and type as major determinants of the Huntington’s disease (HD)-affected population. The report highlights patterns in the prevalence of Huntington’s disease (HD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Huntington’s Disease in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Huntington’s Disease (HD) Disease Overview

Huntington's disease is an incurable neurodegenerative disorder that causes damage to the brain cells. It can lead to loss of intellectual abilities, emotional disturbances, and uncontrolled movements. Adult-onset form of the disease is the most prevalent type, appearing in individuals aged 30 to 40 years. On the other hand, juvenile Huntington's disease appears in children and adolescents and occurs rarely.

• According to various epidemiological studies published between 2010 and 2022, the pooled incidence and prevalence were estimated to be 0.48 cases and 4.88 cases per 100,000 person-years, respectively.
• As per the statistics published by the University of California San Francisco (UCSF Health), around 1 in every 10,000 to 20,000 people are affected by Huntingdon’s disease in the United States. The symptoms usually begin between the ages of 30 and 55. This neurodegenerative disease occurs in both males and females equally.
• A 2021 review article published in the International Journal of Pharmacy and Pharmaceutical Sciences reported that Huntington’s disease affects 2.7 per 100,000 people worldwide.
• DZNE, the German Center for Neurodegenerative Diseases, states that approximately 10,000 people are living with Huntingdon’s disease in Germany and around 30,000 people are carrying the Huntington’s gene.

Huntington’s Disease (HD): Treatment Overview

Currently, there is no cure for Huntingdon’s disease. However, certain medications that can help in the management of symptoms are available. Haloperidol, tetrabenazine, and amantadine are some of the commonly prescribed drugs that are used in the treatment of unusual movements. For delusional thoughts and hallucinations, drugs like haloperidol and tetrabenazine are given to the patients. Antidepressants and antianxiety are often prescribed to patients experiencing symptoms of depression and suicidal thoughts.

Epidemiology

The Huntington’s disease (HD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Huntington’s disease (HD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Huntington’s disease (HD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Country-wise Huntington’s Disease (HD) Epidemiology

The Huntington’s Disease (HD) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

As per the continent-specific subgroup analysis published in the Movement Disorders Journal (2022), countries in Europe and North America were reported to show a higher incidence of Huntington’s disease compared to Asian countries. Further, it is estimated that the slight increase in the prevalence of the condition in European and North American countries such as the United States is likely due to the greater availability of molecular testing, increased life expectancy, earlier diagnosis, and de novo mutations.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Huntington’s disease (HD) based on several factors.
• Huntington’s Disease (HD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population and the unmet needs of Huntington’s disease (HD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Huntington’s disease (HD) epidemiology in 8MM?
• What will be the total number of patients with Huntington’s disease (HD) across the 8MM during the forecast period (2025-2034)?
• What was the country-wise prevalence of Huntington’s disease (HD) in the 8 major markets in the historical period?
• Which country will have the highest number of Huntington’s disease (HD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Huntington’s disease (HD) during the forecast period of 2025-2034?
• What are the currently available treatments for Huntington’s disease (HD)?
• What are the disease risks, signs & symptoms, and unmet needs of Huntington’s disease (HD)?

This product will be delivered within 3-5 business days.